Related Experiment Video
Updated: Aug 6, 2026
09:45
Photodynamic Therapy with Blended Conducting Polymer/Fullerene Nanoparticle Photosensitizers
Published on: October 28, 2015
Supramolecular photonic therapeutic agents
Shane O McDonnell1, Michael J Hall, Lorcan T Allen
1Centre for Synthesis and Chemical Biology, Conway Institute, School of Chemistry and Chemical Biology, University College Dublin, Belfield, Dublin 4, Ireland.
Journal of the American Chemical Society
|November 25, 2005
Summary
Researchers developed a new photodynamic therapy agent that can be switched on/off using pH changes. This supramolecular photonic therapeutic agent (SPTA) selectively generates singlet oxygen for targeted cancer treatment.
Area of Science:
- Photodynamic Therapy
- Supramolecular Chemistry
- Chemical Biology
Background:
- Photodynamic therapy (PDT) relies on photosensitizers to generate cytotoxic singlet oxygen.
- Achieving selectivity in PDT remains a challenge, often leading to off-target effects.
- Developing stimuli-responsive agents can enhance therapeutic precision.
Purpose of the Study:
- To design and synthesize a supramolecular photonic therapeutic agent (SPTA) with reversible on/off switching of singlet oxygen generation.
- To investigate the pH-responsiveness of SPTAs based on protonation of amine receptors.
- To evaluate the in vitro efficacy and cellular activation of novel SPTA analogues.
Main Methods:
- Synthesis of SPTA analogues incorporating pH-responsive amine receptors with varying pKa values.
- Characterization of singlet oxygen generation dependence on proton concentration.
- Investigation of photoinduced electron transfer (PET) mechanisms in response to pH changes.
- In vitro cellular assays to determine efficacy (EC50) in MRC5 cell line.
Main Results:
- Demonstrated reversible on/off switching of singlet oxygen generation in SPTAs.
- Singlet oxygen production was shown to be dependent on protonation of the amine receptor.
- Protonation of the amine receptor inhibited the PET mechanism, enabling singlet oxygen production.
- One SPTA analogue exhibited potent in vitro efficacy with an EC50 of 5.8 nM in MRC5 cells.
Conclusions:
- Developed a novel pH-responsive SPTA platform for controlled photodynamic therapy.
- The reversible on/off switching mechanism offers enhanced selectivity for cancer treatment.
- The high efficacy of the lead analogue warrants further investigation for clinical applications.
